18 November 2021
Dr. Vladimir Cmiljanovic, CEO and founder of Swiss Rockets AG and RocketVax AG, has been named as the recipient of the 2021 Nikola Tesla Award for his accomplishments in the field of science.
Nikola Tesla Award is a prestigious, national award given by the Government of the Republic of Serbia and the Ministry of Foreign Affairs. The laureates of this award are prominent individuals of Serbian origin who have contributed to the promotion of Serbia and the strengthening of ties between the motherland and Serbs in the region and the diaspora.
Dr. Vladimir Cmiljanovic has been named as the recipient of the Nikola Tesla Award for advocating the achievements of Serbian scientists in the world through his scientific attainments in the field of oncology, as well as for leading the team of experts in the development of the second generation of SARS-CoV-2 vaccine.
Since the award is of national importance, official state institutions and media representatives paid special attention to this event.
To read the full report given by The Government of the Republic of Serbia, click on the file below:
To see the interviews that Dr. Vladimir Cmiljanovic gave on this occasion, watch the videos below:
Source: PRVA TV
Source: K1 TV/Youtube
18 April 2022
Several Swiss biotech and pharmaceutical companies are developing vaccines or drugs against the COVID-19 disease. One of them is ROCKETVAX. You can read more about the projects on the link below: Seite_6_FUW_2022-03-30 Source: Finanz und Wirtschaft Share
28 March 2022
Covid will remain a dangerous disease in 2022, says Volker Thiel. To change that, he is developing nasal vaccines that could be produced in Switzerland. To read the full article, click on the link below: Es_kann_eine_Sommerwelle_geben Share
28 March 2022
Research cooperation of a NRP 78 research team with the biotech company RocketVax AG to prepare clinical trials on two vaccine candidates. Researchers from Bern, Geneva, Berlin and Riems (Germany) are developing two vaccine candidates against SARS-CoV-2. Thanks to a just-signed collaboration agreement with the Basel-based biotech company RocketVax AG, they can now be prepped […]
28 March 2022
RocketVax is developing the second-generation COVID-19 vaccine while using the live attenuated SARS-CoV-2 virus vaccine with following differentiation points: ● it provides a longer-lasting immune response resulting from T-cell activation; ● the vaccine is effective despite mutations on the coronavirus spike protein because it contains all viral proteins and not only the spike protein; ● […]
30 September 2021
“The research team of the company ‘Swiss Rockets‘ is working on a vaccine based on a weakened coronavirus,” explains the guest of the ‘Morning program’, Dr. Vladimir Cmiljanovic. “It will be a second-generation vaccine that, unlike the first-generation vaccines, such as the mRNA or the Oxford and Russian vaccines, which have only spike protein as […]